🚀 VC round data is live in beta, check it out!
United Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for United Therapeutics and similar public comparables like BioNTech, Biogen, Astellas Pharma, Royalty Pharma and more.
United Therapeutics Overview
About United Therapeutics
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
Founded
1996
HQ
Employees
1.4K
Website
Sectors
Financials (LTM)
EV
$23B
United Therapeutics Financials
United Therapeutics reported last 12-month revenue of $3B and EBITDA of $2B.
In the same LTM period, United Therapeutics generated $3B in gross profit, $2B in EBITDA, and $1B in net income.
Revenue (LTM)
United Therapeutics P&L
In the most recent fiscal year, United Therapeutics reported revenue of $3B and EBITDA of $2B.
United Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Profit | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Margin | 88% | XXX | 88% | XXX | XXX | XXX |
| EBITDA | $2B | XXX | $2B | XXX | XXX | XXX |
| EBITDA Margin | 53% | XXX | 57% | XXX | XXX | XXX |
| EBIT Margin | 47% | XXX | 48% | XXX | XXX | XXX |
| Net Profit | $1B | XXX | $1B | XXX | XXX | XXX |
| Net Margin | 41% | XXX | 42% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
United Therapeutics Stock Performance
United Therapeutics has current market cap of $26B, and enterprise value of $23B.
Market Cap Evolution
United Therapeutics' stock price is $588.21.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $23B | $26B | 1.3% | XXX | XXX | XXX | $30.45 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialUnited Therapeutics Valuation Multiples
United Therapeutics trades at 7.0x EV/Revenue multiple, and 13.3x EV/EBITDA.
EV / Revenue (LTM)
United Therapeutics Financial Valuation Multiples
As of April 18, 2026, United Therapeutics has market cap of $26B and EV of $23B.
Equity research analysts estimate United Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
United Therapeutics has a P/E ratio of 19.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $26B | XXX | $26B | XXX | XXX | XXX |
| EV (current) | $23B | XXX | $23B | XXX | XXX | XXX |
| EV/Revenue | 7.0x | XXX | 7.1x | XXX | XXX | XXX |
| EV/EBITDA | 13.3x | XXX | 12.5x | XXX | XXX | XXX |
| EV/EBIT | 14.9x | XXX | 14.9x | XXX | XXX | XXX |
| EV/Gross Profit | 8.0x | XXX | 8.1x | XXX | XXX | XXX |
| P/E | 19.3x | XXX | 19.3x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 21.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified United Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
United Therapeutics Margins & Growth Rates
United Therapeutics' revenue in the last 12 month grew by 7%.
United Therapeutics' revenue per employee in the last FY averaged $2.3M, while opex per employee averaged $0.9M for the same period.
United Therapeutics' rule of 40 is 55% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
United Therapeutics' rule of X is 60% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
United Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 53% | XXX | 57% | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | (7%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 55% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 60% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $2.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 19% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 17% | XXX | 17% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
United Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| United Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| BioNTech | XXX | XXX | XXX | XXX | XXX | XXX |
| Biogen | XXX | XXX | XXX | XXX | XXX | XXX |
| Astellas Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Royalty Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Roivant Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
United Therapeutics M&A Activity
United Therapeutics acquired XXX companies to date.
Last acquisition by United Therapeutics was on XXXXXXXX, XXXXX. United Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by United Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialUnited Therapeutics Investment Activity
United Therapeutics invested in XXX companies to date.
United Therapeutics made its latest investment on XXXXXXXX, XXXXX. United Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by United Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout United Therapeutics
| When was United Therapeutics founded? | United Therapeutics was founded in 1996. |
| Where is United Therapeutics headquartered? | United Therapeutics is headquartered in United States. |
| How many employees does United Therapeutics have? | As of today, United Therapeutics has over 1K employees. |
| Who is the CEO of United Therapeutics? | United Therapeutics' CEO is Martine A. Rothblatt. |
| Is United Therapeutics publicly listed? | Yes, United Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of United Therapeutics? | United Therapeutics trades under UTHR ticker. |
| When did United Therapeutics go public? | United Therapeutics went public in 1999. |
| Who are competitors of United Therapeutics? | United Therapeutics main competitors are BioNTech, Biogen, Astellas Pharma, Royalty Pharma. |
| What is the current market cap of United Therapeutics? | United Therapeutics' current market cap is $26B. |
| What is the current revenue of United Therapeutics? | United Therapeutics' last 12 months revenue is $3B. |
| What is the current revenue growth of United Therapeutics? | United Therapeutics revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of United Therapeutics? | Current revenue multiple of United Therapeutics is 7.0x. |
| Is United Therapeutics profitable? | Yes, United Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of United Therapeutics? | United Therapeutics' last 12 months EBITDA is $2B. |
| What is United Therapeutics' EBITDA margin? | United Therapeutics' last 12 months EBITDA margin is 53%. |
| What is the current EV/EBITDA multiple of United Therapeutics? | Current EBITDA multiple of United Therapeutics is 13.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.